Dec 14 (Reuters) - ProMetic Life Sciences Inc PLI.TO :
* Prometic's PBI-4050 to target Cystic Fibrosis (CF) as its next orphan indication
* Double-blind placebo-controlled phase II trial to focus on pancreatic
fibrosis, glucose intolerance, diabetes in CF patients
* Source text for Eikon
* Further company coverage PLI.TO